PDS Biotechnology Corporation (PDSB) financial statements (2022 and earlier)

Company profile

Business Address 25B VREELAND ROAD
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments65,24328,84012,16234,64688,068106,399130,189
Cash and cash equivalents65,24328,84012,16234,64688,068106,399130,189
Other undisclosed current assets1,5981,4982,3081,0069879551,081
Total current assets:66,84030,33714,47035,65189,054107,354131,271
Noncurrent Assets
Operating lease, right-of-use asset358548 
Property, plant and equipment05214273,4243,4182,767
Intangible assets, net (including goodwill)  2,974    
Intangible assets, net (excluding goodwill)  2,974    
Other noncurrent assets   14314314355
Other undisclosed noncurrent assets  (2,974)    
Total noncurrent assets:358553215703,5673,5612,822
TOTAL ASSETS:67,19830,89014,49136,22192,621110,914134,093
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,4973,1512,2958199,7916,6856,319
Accounts payable1,3091,4151,1983994,3693,4712,584
Accrued liabilities2,1881,7351,0984195,4223,2143,734
Debt    3,075 2,271
Restructuring reserve  4985,563   
Other undisclosed current liabilities259120     
Total current liabilities:3,7563,2702,7946,38212,8676,6858,590
Noncurrent Liabilities
Long-term debt and lease obligation231490  17,38314,9533,025
Long-term debt, excluding current maturities    17,38314,9533,025
Operating lease, liability231490 
Other undisclosed noncurrent liabilities(231)(490)     
Total noncurrent liabilities:231490  17,38314,9533,025
Total liabilities:3,9873,7612,7946,38230,25021,63811,615
Stockholders' equity
Stockholders' equity attributable to parent63,21027,13011,69829,83962,37189,277122,478
Common stock97211101010
Additional paid in capital123,90570,90740,634222,645214,309190,342184,722
Accumulated deficit(60,704)(43,785)(28,938)(192,816)(151,948)(101,075)(62,254)
Total stockholders' equity:63,21027,13011,69829,83962,37189,277122,478
TOTAL LIABILITIES AND EQUITY:67,19830,89014,49136,22192,621110,914134,093

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(21,439)(14,902)(21,035)(43,097)(51,967)(39,512)(26,499)
Operating loss:(21,439)(14,902)(21,035)(43,097)(51,967)(39,512)(26,499)
Nonoperating income45513,688872701499
Investment income, nonoperating45513,6888727012129
Other nonoperating expense     (163) 
Interest and debt expense  (34)(1,425)(2,180)(1,204)(816)
Other undisclosed loss from continuing operations before equity method investments, income taxes      (1,880)
Loss from continuing operations before income taxes:(21,435)(14,847)(7,380)(43,650)(53,446)(40,667)(29,186)
Income tax expense (benefit)4,516 (382)2,7822,5861,8461,107
Net loss:(16,918)(14,847)(7,762)(40,868)(50,860)(38,821)(28,079)
Other undisclosed net income attributable to parent  763    
Net loss attributable to parent:(16,918)(14,847)(6,999)(40,868)(50,860)(38,821)(28,079)
Preferred stock dividends and other adjustments      (4,356)
Net loss available to common stockholders, diluted:(16,918)(14,847)(6,999)(40,868)(50,860)(38,821)(32,435)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(16,918)(14,847)(7,762)(40,868)(50,860)(38,821)(28,079)
Comprehensive loss:(16,918)(14,847)(7,762)(40,868)(50,860)(38,821)(28,079)
Other undisclosed comprehensive income, net of tax, attributable to parent  763    
Comprehensive loss, net of tax, attributable to parent:(16,918)(14,847)(6,999)(40,868)(50,860)(38,821)(28,079)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: